ID   INA-6
AC   CVCL_5209
SY   INA6
DR   BTO; BTO:0004745
DR   EFO; EFO_0005386
DR   BioSample; SAMN10989605
DR   cancercelllines; CVCL_5209
DR   Cell_Model_Passport; SIDM01555
DR   Cosmic; 1424216
DR   Cosmic; 1483075
DR   Cosmic; 2081383
DR   DepMap; ACH-000512
DR   DSMZ; ACC-862
DR   DSMZCellDive; ACC-862
DR   Wikidata; Q54897699
RX   CelloPub=CLPUB00060;
RX   CelloPub=CLPUB00604;
RX   PubMed=10936422;
RX   PubMed=11920233;
RX   PubMed=17692805;
RX   PubMed=18647998;
RX   PubMed=19621390;
RX   PubMed=22806891;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=32123307;
WW   https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics
WW   http://www.cells-talk.com/index.php/page/copelibrary?key=INA-6
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   Characteristics: Produces Ig kappa.
CC   Characteristics: IL6 dependent.
CC   Doubling time: ~30-50 hours (DSMZ=ACC-862).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Met (c.395A>T); ClinVar=VCV000376629; Zygosity=Heterozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Ter (c.991C>T); ClinVar=VCV000922893; Zygosity=Heterozygous (DepMap).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.46%; Native American=0.15%; East Asian, North=2.2%; East Asian, South=0%; South Asian=0%; European, North=63.38%; European, South=33.82% (PubMed=30894373).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): DSMZ
ST   Amelogenin: X,Y
ST   CSF1PO: 10,13
ST   D13S317: 8,12
ST   D16S539: 9,11
ST   D18S51: 12,15
ST   D19S433: 14,15
ST   D21S11: 29,30
ST   D2S1338: 16
ST   D3S1358: 15,16
ST   D5S818: 12,13
ST   D7S820: 11,12
ST   D8S1179: 14
ST   FGA: 21,22
ST   Penta D: 9
ST   Penta E: 7,12
ST   TH01: 9,9.3
ST   TPOX: 8
ST   vWA: 18
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   80Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 26
//
RX   CelloPub=CLPUB00060;
RA   Gramatzki M., Burger R., Trautmann U., Marschalek R., Lorenz H.,
RA   Hansen-Hagge T.E., Baum W., Bartram C.R., Gebhart E., Kalden J.R.;
RT   "Two new interleukin-6 dependent plasma cell lines carrying a
RT   chromosomal abnormality involving the IL-6 gene locus.";
RL   Blood 84 Suppl. 1:173a-173a(1994).
//
RX   CelloPub=CLPUB00604;
RA   Chow S.;
RT   "Targeted capture and sequencing of immunoglobulin rearrangements
RT   in multiple myeloma to enable detection of minimal residual disease.";
RL   Thesis MSc (2017), University of Toronto, Canada.
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   PubMed=11920233; DOI=10.1038/sj.thj.6200075;
RA   Burger R., Guenther A., Bakker F., Schmalzing M., Bernand S., Baum W.,
RA   Duerr B., Hocke G.M., Steininger H., Gebhart E., Gramatzki M.;
RT   "Gp130 and ras mediated signaling in human plasma cell line INA-6: a
RT   cytokine-regulated tumor model for plasmacytoma.";
RL   Hematol. J. 2:42-53(2001).
//
RX   PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003;
RA   Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J.,
RA   Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T.,
RA   Zhu Y.-X., Fogle H., Price-Troska T.L., Ahmann G.J., Mancini C.,
RA   Brents L.A., Kumar S.K., Greipp P., Dispenzieri A., Bryant B.,
RA   Mulligan G., Bruhn L., Barrett M.T., Valdez R., Trent J.M.,
RA   Stewart A.K., Carpten J.D., Bergsagel P.L.;
RT   "Promiscuous mutations activate the noncanonical NF-kappaB pathway in
RT   multiple myeloma.";
RL   Cancer Cell 12:131-144(2007).
//
RX   PubMed=18647998; DOI=10.1093/jncimonographs/lgn011;
RA   Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.;
RT   "Characterization of MYC translocations in multiple myeloma cell
RT   lines.";
RL   J. Natl. Cancer Inst. Monogr. 39:25-31(2008).
//
RX   PubMed=19621390; DOI=10.1002/ijc.24758;
RA   Guenther A., Gordon S., Tiemann M., Burger R., Bakker F., Green J.R.,
RA   Baum W., Roelofs A.J., Rogers M.J., Gramatzki M.;
RT   "The bisphosphonate zoledronic acid has antimyeloma activity in vivo
RT   by inhibition of protein prenylation.";
RL   Int. J. Cancer 126:239-246(2010).
//
RX   PubMed=22806891; DOI=10.1182/blood-2011-08-371567;
RA   Holien T., Vatsveen T.K., Hella H., Waage A., Sundan A.;
RT   "Addiction to c-MYC in multiple myeloma.";
RL   Blood 120:2450-2453(2012).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=32123307; DOI=10.1038/s41375-020-0785-1;
RA   Sarin V., Yu K., Ferguson I.D., Gugliemini O., Nix M.A., Hann B.,
RA   Sirota M., Wiita A.P.;
RT   "Evaluating the efficacy of multiple myeloma cell lines as models for
RT   patient tumors via transcriptomic correlation analysis.";
RL   Leukemia 34:2754-2765(2020).
//